News

Three studies provide insights into the ongoing COVID-19 pandemic, the prevalence of post-COVID conditions among primary care patients, the effectiveness of nirmatrelvir/ritonavir treatment, and declines in primary care visits.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.

Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.

This upcoming Sunday, July 28, is this year’s World Hepatitis Day and it is an opportunity to raise awareness, deliver education to the masses, and continue to support the research and treatments to reduce the incidence rates of the infection.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.

Evaluating nirmatrelvir–ritonavir over 5-10 days for post-exposure prophylaxis revealed no reduction in symptomatic SARS-CoV-2 infections compared to placebo among asymptomatic adults.

CDC reports 2 deaths so far, and several more people sickened across multiple states.

This week, the resurgence of leptospirosis in Wyoming, insights on COVID-19 reinfection severity, avian influenza cases in the US, challenges in medical communication amid scientific advancements, recent FDA recalls, and more from Contagion.

Participants of the phase 3 trial for the Pfizer and Valneva vaccine candidate, VLA15, received their immunizations and everyone will be observed through next year’s Lyme disease season.

A large study from the Veterans Affairs shows an association between being unvaccinated and a greater incidence rate of Long COVID.

With an efficacy rate of 78% and WHO prequalification, the vaccine rollout aims to vaccinate 6.6 million children across 15 African countries by the end of 2024, marking an advancement in public health efforts to combat malaria's impact

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

The disconnect between evolving science and medical communication has left people confused about how to interpret public health information, and provided an opportunity for vaccine deniers and politicians to give disinformation on COVID-19.

A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.

A Salmonella outbreak associated with Raw Farm in Fresno, California, has sickened at least 165 people, marking the largest US outbreak linked to raw milk in the past decade.

The OraQuick HCV self-test aims to improve testing access and help individuals detect the disease affecting an estimated 58 million people worldwide.

Epidemiologist Courtney Tillman, MPH, emphasizes the importance of routine vaccinations and awareness of occupational risks to prevent human infections.

Emily Hadley highlights study findings showing a higher incidence of Long COVID following initial infections compared to reinfections, particularly during the Omicron period among 3 million patients.

The individuals who worked in an egg layer facility in Colorado were confirmed to have H5N1 and they have reported mild symptoms without hospitalizations.

The company acquired rights from CureVac to develop vaccines for influenza and COVID-19 using the mRNA platform.

An outside physician who was working at 3 hospitals in the Portland, Oregon area did not follow infection prevention protocols, leaving patients potentially exposed to bloodborne infections.

The FDA has overseen multiple product recalls this July thus far, including mystery infections linked to 58 illnesses, listeria, salmonella, plastic contamination, and more prompting the recall of various products.

Clinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.

Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.